Zishenpingchan granules for the treatment of Parkinson's disease:a randomized,double-blind,placebo-controlled clinical trial

被引:6
|
作者
Qing Ye [1 ]
Xiao-Lei Yuan [1 ]
Can-Xing Yuan [1 ]
Hong-Zhi Zhang [2 ]
Xu-Ming Yang [3 ]
机构
[1] Department of Neurology,LONGHUA Hospital,Shanghai University of Traditional Chinese Medicine
[2] Department of Neurology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
[3] Acupuncture and Tuina College of Shanghai University of Traditional Chinese Medicine
基金
中国国家自然科学基金;
关键词
nerve regeneration; levodopa; motion complications; non-motor symptoms; traditional Chinese medicine treatment; artificial neural networks; Zishenpingchan granules; randomized controlled trials; neurodegenerative diseases; neural regeneration;
D O I
暂无
中图分类号
R277.7 [中医神经病学与精神病学];
学科分类号
1005 ;
摘要
Levodopa preparations remain the preferred drug for Parkinson’s disease.However,long-term use of levodopa may lead to a series of motor complications.Previous studies have shown that the combination of levodopa and Zishenpingchan granules(consisting of Radix Rehmanniae preparata,Lycium barbarum,Herba Taxilli,Rhizoma Gastrodiae,Stiff Silkorm,Curcuma phaeocaulis,Radix Paeoniae Alba,Rhizoma Arisaematis,Scorpio and Centipede) can markedly improve dyskinesia and delay the progression of Parkinson’s disease,with especially dramatic improvements of non-motor symptoms.However,the efficacy of this combination has not been confirmed by randomized controlled trials.The current study was approved by the Hospital Ethics Committee and was registered in the Chinese Clinical Trial Register(registration number:Chi CTR-INR-1701194).From December 2014 to December 2016,128 patients(72 males and 56 females,mean age of 65.78 ± 6.34 years) with Parkinson’s disease were recruited from the Department of Neurology of Longhua Hospital and Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine in China.Patients were equally allocated into treatment and control groups.In addition to treatment with dopamine,patients in treatment and control groups were given Zishenpingchan granules or placebo,respectively,for 24 weeks.Therapeutic efficacy was assessed using the Unified Parkinson’s Disease Rating Scale,on-off phenomenon,Hoehn-Yahr grade,Scales for Outcomes in Parkinson’s disease–Autonomic,Parkinson’s disease sleep scale,Hamilton Anxiety Scale,Hamilton Depression Scale,Mini-Mental State Examination,and the Parkinson’s Disease Quality of Life Questionnaire.Artificial neural networks were used to determine weights at which to scale these parameters.Our results demonstrated that Zishenpingchan granules significantly reduced the occurrence of motor complications,and were useful for mitigating dyskinesia and non-motor symptoms of Parkinson’s disease.This combination of Chinese and Western medicine has the potential to reduce levodopa dosages,and no obvious side effects were found.These findings indicate that Zishenpingchan granules can mitigate symptoms of Parkinson’s disease,reduce toxic side effects of dopaminergic agents,and exert synergistic and detoxifying effects.
引用
收藏
页码:1269 / 1275
页数:7
相关论文
共 50 条
  • [1] Zishenpingchan granules for the treatment of Parkinson's disease: a randomized, double-blind, placebo-controlled clinical trial
    Ye, Qing
    Yuan, Xiao-Lei
    Yuan, Can-Xing
    Zhang, Hong-Zhi
    Yang, Xu-Ming
    [J]. NEURAL REGENERATION RESEARCH, 2018, 13 (07) : 1269 - 1275
  • [2] A Randomized, Double-Blind, Placebo-Controlled Trial of Camicinal in Parkinson's Disease
    Marrinan, Sarah L.
    Otiker, Tal
    Vasist, Lakshmi S.
    Gibson, Rachel A.
    Sarai, Bhopinder K.
    Barton, Matthew E.
    Richards, Duncan B.
    Hellstrom, Per M.
    Nyholm, Dag
    Dukes, George E.
    Burn, David J.
    [J]. MOVEMENT DISORDERS, 2018, 33 (02) : 329 - 332
  • [3] A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
    Richard, I. H.
    McDermott, M. P.
    Kurlan, R.
    Lyness, J. M.
    Como, P. G.
    Pearson, N.
    Factor, S. A.
    Juncos, J.
    Ramos, C. Serrano
    Brodsky, M.
    Manning, C.
    Marsh, L.
    Shulman, L.
    Fernandez, H. H.
    Black, K. J.
    Panisset, M.
    Christine, C. W.
    Jiang, W.
    Singer, C.
    Horn, S.
    Pfeiffer, R.
    Rottenberg, D.
    Slevin, J.
    Elmer, L.
    Press, D.
    Hyson, H. C.
    McDonald, W.
    [J]. NEUROLOGY, 2012, 78 (16) : 1229 - 1236
  • [4] Effects of ETyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
    DiFrancisco-Donoghue, Joanne
    Rabin, Ely
    Lamberg, Eric M.
    Werner, William G.
    [J]. MOVEMENT DISORDERS CLINICAL PRACTICE, 2014, 1 (04): : 348 - 353
  • [5] A randomized, double-blind, placebo-controlled trial of hydrogen water in Parkinson's disease
    Yoritaka, A.
    Takanashi, M.
    Hirayama, M.
    Ohta, S.
    Hattori, N.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 311 - 311
  • [6] A randomized double-blind placebo-controlled trial of probiotics for constipation in Parkinson's disease
    Chong, K. K.
    Lim, S. Y.
    Manap, M. A. A. A.
    Lim, J. L.
    Low, S. C.
    Mahadeva, S. K.
    Tan, A. H.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S194 - S194
  • [7] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    [J]. MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
  • [8] Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
    Goetz, Christopher G.
    Damier, Philippe
    Hicking, Christine
    Laska, Eugene
    Mueller, Thomas
    Olanow, C. Warren
    Rascol, Olivier
    Russ, Hermann
    [J]. MOVEMENT DISORDERS, 2007, 22 (02) : 179 - 186
  • [9] Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Nomoto, Masahiro
    Mizuno, Yoshikuni
    Kondo, Tomoyoshi
    Hasegawa, Kazuko
    Murata, Miho
    Takeuchi, Masahiro
    Ikeda, Junji
    Tomida, Takayuki
    Hattori, Nobutaka
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 (10) : 1887 - 1893
  • [10] Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial
    Masahiro Nomoto
    Yoshikuni Mizuno
    Tomoyoshi Kondo
    Kazuko Hasegawa
    Miho Murata
    Masahiro Takeuchi
    Junji Ikeda
    Takayuki Tomida
    Nobutaka Hattori
    [J]. Journal of Neurology, 2014, 261 : 1887 - 1893